A pilot study of verapamil in the treatment of tardive dyskinesia
β Scribed by Timothy G. Dinan; Claire Capstick
- Publisher
- John Wiley and Sons
- Year
- 1989
- Tongue
- English
- Weight
- 237 KB
- Volume
- 4
- Category
- Article
- ISSN
- 0885-6222
No coin nor oath required. For personal study only.
β¦ Synopsis
Six patients with severe and stable tardive dyskinesia were treated with verapamil, a calcium channel blocker, in doses ranging from 240 to 400 mg/day. Weekly assessments were made using the Simpson tardive dyskinesia rating scale. Neuroleptic medication was held constant during the 3-month baseline assessment and during the month of treatment with verapamil. Four of the six patients showed a dramatic response to treatment and a fifth showed a slight improvement. The four good responders were younger and had the tardive dyskinesia for a shorter period of time.
π SIMILAR VOLUMES
## Abstract We evaluated the tolerability and preliminary efficacy of levetiracetam (LEV; Keppra) in reducing levodopaβinduced dyskinesias in Parkinson's disease (PD) in an openβlabel pilot study. Nine PD patients who were experiencing peakβdose dyskinesias for at least 25% of the awake day and wer
## Abstract Tardive dyskinesia (TD), which is frequently seen in patients treated with dopamine receptor blocking agents, is difficult to manage. We report on a young Chinese man with bipolar disorder who developed TD after haloperidol treatment, involving the trunk, limbs, and orofacial area. TD p